A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed

Trial end date:
2012-03-01

Target enrollment:

Participant gender:

The purpose of this study is to provide pivotal efficacy and safety data for QVA149 in patients with moderate to severe COPD.

Phase 3

Novartis Pharmaceuticals

Glycopyrrolate
Tiotropium Bromide